News, Short Squeeze, Breakout and More Instantly...
Tyra Biosciences Reports First Quarter 2022 Financial Results and Highlights PR Newswire -Pipeline on-track; INDs to be filed for TYRA-300 and TYRA-200 in 2022- -Well-capitalized with cash and cash equivalents of $292.5 million as of Q1 2022- CARL...
Tyra Biosciences Reports Fourth Quarter and Full Year 2021 Financial Results and Highlights -Pipeline on-track; INDs expected to be filed for TYRA-300 and TYRA-200 in 2022- -Strengthened organization with key appointment to clinical team- -Well-capitalized with cash and ...
Tyra Biosciences to Participate in Cowen 42nd Annual Healthcare Conference PR Newswire CARLSBAD, Calif. , Feb. 22, 2022 /PRNewswire/ -- Tyra Biosciences, Inc. (Nasdaq: TYRA), a precision oncology company focused on developing purpose-built therapies to overcome t...